Slide kit describing the effectiveness of using a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).
Slide-Kit
Poster presented at ASH 2022 evaluating BCL-2 inhibition in combination with chemotherapy for treatment-naïve (TN) or relapsed/refractory (R/R) acute myeloid leukemia (AML) patients.
Reading
Poster presented at ASH 2022 evaluating BTKi treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients.
Reading
Poster presented at ASH 2022 describing the genomic analysis of patients with R/R B‑cell malignancies who were previously intolerant to certain BTKi’s.
Reading
Poster presented at ASH 2022 evaluating the use of BTKi in Japanese patients with B-cell malignancies.
Reading
